Sector consensus Genmab A/S Nasdaq

Stocks

Real-time Estimate Cboe BZX 12:41:26 2026-09-04 EDT			5-day change	1st Jan Change
33.78 ^USD	-1.82%		+1.66%	+9.68%

09-03	Handelsbanken Adds Xvivo and Vimian as Sector Favorites, Drops Danish Duo	FW
09-01	Deutsche Bank raises price target for Genmab to 2,500 Danish kroner, reiterates buy	FW

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' target price evolution (4 months)	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Average Target P.	Objective/dr gap	Nbr of analysts
GENMAB A/S	-	-	-	-	-	-	-
WUXI APPTEC CO., LTD.					186.27	+18.92%	18
ARGENX SE					1,162.61	+9.64%	15
INSMED INCORPORATED					200.18	+58.02%	22
BIONTECH SE					103.61	+16.97%	20
WUXI BIOLOGICS (CAYMAN) INC.					49.16	+13.1%	24
GENMAB A/S					2,427.12	+10.47%	15
PHARMAESSENTIA CORPORATION					1,397.26	+3.5%	8
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					618.43	+24.48%	18
EXELIXIS, INC.					53.69	-9.2%	16
MADRIGAL PHARMACEUTICALS, INC.					678.06	+24.96%	16
ARROWHEAD PHARMACEUTICALS, INC.					110.18	+27.39%	11
SUMMIT THERAPEUTICS INC.					21.01	+66%	13
AKESO, INC.					134.69	+73.07%	21
CYTOKINETICS, INCORPORATED					109.9	+48.61%	20
VAXCYTE, INC.					109	+78.19%	9
REMEGEN CO., LTD.					100.21	+43.81%	16
IMMUNITYBIO, INC.					12.75	+55.68%	4
SPYRE THERAPEUTICS, INC.					119.71	+37.21%	14
SHANGHAI ALLIST PHARMACEUTICALS CO., LTD.			-	-	-	-	-
Average					421.88	+33.38%	16
Weighted average by Cap.					528.99	+25.33%	17